Fig. 4

The JAK-STAT pathway is constitutively activated in chidamide-resistant NKTL. A The JAK-STAT oncogenic signaling pathway was activated in chidamide-resistant cells. B Hierarchical clustering of DEGs from the JAK-STAT pathway in sensitive versus resistant cells. C RT–qPCR validation of genes from the JAK-STAT pathway in sensitive and resistant cells. D Representative images of IHC for CD30 in NKTL biopsies. Scale bars: 50 μm. E Association between the expression of CD30 and clinical response. The expression of CD30 in 23 NKTL biopsies (available from the 28 relapsed/refractory NKTL patients) was examined by IHC. p = 0.0272 for association by Fisher’s exact test. F Waterfall plot showing the association between the expression of CD30 and the best overall response to chidamide in 23 patients. The results are expressed as the mean ± SD of three independent experiments